Michael Korn, MD

Title(s)Volunteer Clinical Professor, Medicine
SchoolSchool of Medicine
AddressRemote Location, #001
Varies 00001
Phone415-502-2844
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Heinrich-Heine University of DuesseldorfM.D.1988School of Medicine

    Collapse Overview 
    Collapse Overview
    Dr. Korn's is an expert on gastrointestinal cancers, with focus on esophageal, gastric, and pancreatic, and colon cancers. He initiated and chairs the UCSF Molecular Tumor Board and has a strong clinical as well as research interest in precision oncology. He is principal investigator on clinical trials of novel anti-cancer agents as part of the Phase-I Clinical Trials program and leads trials in esophageal and gastric cancers., Dr. Korn's laboratory research focuses on systems biology and computational models of signal transduction in cancer, as well as design of rational combination therapies targeting receptor tyrosine kinase signaling, and the MAPK and PI3K pathways.

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing. BMC Cancer. 2023 Oct 18; 23(1):1000. Nagasaka M, Zhang SS, Baca Y, Xiu J, Nieva J, Vanderwalde A, Swensen JJ, Spetzler D, Korn WM, Raez LE, Liu SV, Ou SI. PMID: 37853341; PMCID: PMC10585918.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    2. Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset. Transl Oncol. 2023 Oct; 36:101744. Nagasaka M, Brazel D, Baca Y, Xiu J, Al-Hallak MN, Kim C, Nieva J, Swensen JJ, Spetzler D, Korn WM, Socinski MA, Raez LE, Halmos B, Ou SI. PMID: 37516008; PMCID: PMC10410168.
      View in: PubMed   Mentions: 6  
    3. Genomic and Molecular Profiling of Human Papillomavirus Associated Head and Neck Squamous Cell Carcinoma Treated with Immune Checkpoint Blockade Compared to Survival Outcomes. Cancers (Basel). 2021 Dec 16; 13(24). Shaikh H, McGrath JE, Hughes B, Xiu J, Brodskiy P, Sukari A, Darabi S, Ikpeazu C, Nabhan C, Korn WM, Wise-Draper TM. PMID: 34944929; PMCID: PMC8699559.
      View in: PubMed   Mentions: 8  
    4. Detection of NRG1 Gene Fusions in Solid Tumors. Clin Cancer Res. 2019 Aug 15; 25(16):4966-4972. Jonna S, Feldman RA, Swensen J, Gatalica Z, Korn WM, Borghaei H, Ma PC, Nieva JJ, Spira AI, Vanderwalde AM, Wozniak AJ, Kim ES, Liu SV. PMID: 30988082; PMCID: PMC7470623.
      View in: PubMed   Mentions: 93     Fields:    Translation:Humans
    5. Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long-term survival outcomes with minimal morbidity. J Surg Oncol. 2016 Dec; 114(7):838-847. Woodard GA, Crockard JC, Clary-Macy C, Zoon-Besselink CT, Jones K, Korn WM, Ko AH, Gottschalk AR, Rogers SJ, Jablons DM. PMID: 27569043.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    6. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016 Feb; 155(3):521-30. Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN. PMID: 26875185.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    7. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clin Cancer Res. 2016 Jan 01; 22(1):61-8. Ko AH, Bekaii-Saab T, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasaz A, Kuhn P, Tempero MA, Collisson EA, Kelley RK, Venook AP, Dito E, Ong A, Ziyeh S, Courtin R, Linetskaya R, Tahiri S, Korn WM. PMID: 26251290; PMCID: PMC4703532.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCellsCTClinical Trials
    8. Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw. 2015 Feb; 13(2):194-227. Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Besh S, Chao J, Das P, Denlinger C, Fanta P, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Jasperson K, Keswani RN, Kleinberg LR, Korn WM, Leong S, Lockhart AC, Mulcahy MF, Orringer MB, Posey JA, Poultsides GA, Sasson AR, Scott WJ, Strong VE, Varghese TK, Washington MK, Willett CG, Wright CD, Zelman D, McMillian N, Sundar H, National comprehensive cancer network. PMID: 25691612.
      View in: PubMed   Mentions: 188     Fields:    Translation:Humans
    9. 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study. J Gastrointest Cancer. 2014 Jun; 45(2):168-80. Fidelman N, Kerlan RK, Hawkins RA, Taylor AG, Kohi MP, Kolli KP, Bergsland EK, Kelley RK, Ko AH, Korn WM, McWhirter RM, Luan J, Venook AP. PMID: 24448917.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    10. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013 Oct 01; 109(7):1725-34. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. PMID: 24022191; PMCID: PMC3790192.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsCTClinical Trials
    11. Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma. Mol Cancer Ther. 2013 Oct; 12(10):2213-25. Mirzoeva OK, Collisson EA, Schaefer PM, Hann B, Hom YK, Ko AH, Korn WM. PMID: 23918833; PMCID: PMC3800201.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    12. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013 May 01; 11(5):531-46. Ajani JA, Bentrem DJ, Besh S, D'Amico TA, Das P, Denlinger C, Fakih MG, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn WM, Lockhart AC, Meredith K, Mulcahy MF, Orringer MB, Posey JA, Sasson AR, Scott WJ, Strong VE, Varghese TK, Warren G, Washington MK, Willett C, Wright CD, McMillian NR, Sundar H, National Comprehensive Cancer Network. PMID: 23667204.
      View in: PubMed   Mentions: 259     Fields:    Translation:Humans
    13. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol. 2013 Jul; 24(7):1900-1907. Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB, Venook AP. PMID: 23519998; PMCID: PMC3690907.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCellsCTClinical Trials
    14. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol. 2012 Feb; 9(1):016003. Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F, Voigt K, Lazar D, Nieva J, Bazhenova L, Ko AH, Korn WM, Schram E, Coward M, Yang X, Metzner T, Lamy R, Honnatti M, Yoshioka C, Kunken J, Petrova Y, Sok D, Nelson D, Kuhn P. PMID: 22306768; PMCID: PMC3387996.
      View in: PubMed   Mentions: 153     Fields:    Translation:HumansCells
    15. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys Biol. 2012 Feb; 9(1):016001. Cho EH, Wendel M, Luttgen M, Yoshioka C, Marrinucci D, Lazar D, Schram E, Nieva J, Bazhenova L, Morgan A, Ko AH, Korn WM, Kolatkar A, Bethel K, Kuhn P. PMID: 22306705; PMCID: PMC3387999.
      View in: PubMed   Mentions: 114     Fields:    Translation:HumansCells
    16. Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw. 2011 Aug 01; 9(8):830-87. Ajani JA, Barthel JS, Bentrem DJ, D'Amico TA, Das P, Denlinger CS, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn WM, Lockhart AC, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Varghese TK, Warren G, Washington MK, Willett C, Wright CD, National Comprehensive Cancer Network. PMID: 21900218.
      View in: PubMed   Mentions: 109     Fields:    Translation:Humans
    17. ZEB1 limits adenoviral infectability by transcriptionally repressing the coxsackie virus and adenovirus receptor. Mol Cancer. 2011 Jul 27; 10:91. Lacher MD, Shiina M, Chang P, Keller D, Tiirikainen MI, Korn WM. PMID: 21791114; PMCID: PMC3164624.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    18. Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma. J Mol Med (Berl). 2011 Sep; 89(9):877-89. Mirzoeva OK, Hann B, Hom YK, Debnath J, Aftab D, Shokat K, Korn WM. PMID: 21678117.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansAnimalsCells
    19. A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibition. PLoS Comput Biol. 2011 Feb; 7(2):e1001085. Bagheri N, Shiina M, Lauffenburger DA, Korn WM. PMID: 21379332; PMCID: PMC3040662.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    20. Gastric cancer. J Natl Compr Canc Netw. 2010 Apr; 8(4):378-409. Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Das P, Denlinger C, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn M, Meredith K, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Washington MK, Willett C, Wood DE, Wright CD, Yang G, NCCN Gastric Cancer Panel. PMID: 20410333.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    21. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1051-7. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. PMID: 20130876.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    22. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 01; 15(17):5569-75. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. PMID: 19706807; PMCID: PMC3029022.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    23. RNA interference-mediated knockdown of p21(WAF1) enhances anti-tumor cell activity of oncolytic adenoviruses. Cancer Gene Ther. 2009 Nov; 16(11):810-9. Shiina M, Lacher MD, Christian C, Korn WM. PMID: 19407849; PMCID: PMC3076587.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    24. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 2009 Jan 15; 69(2):565-72. Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM, Guan Y, Hu Z, Knight Z, Feiler HS, Gascard P, Parvin B, Spellman PT, Shokat KM, Wyrobek AJ, Bissell MJ, McCormick F, Kuo WL, Mills GB, Gray JW, Korn WM. PMID: 19147570; PMCID: PMC2737189.
      View in: PubMed   Mentions: 190     Fields:    Translation:HumansCells
    25. Esophageal erosion 9 years after anterior cervical plate implantation. Surg Neurol. 2008 Mar; 69(3):310-2; discussion 312-3. Lu DC, Theodore P, Korn WM, Chou D. PMID: 18261766.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    26. Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver. Cancer Gene Ther. 2007 Feb; 14(2):139-50. Au T, Thorne S, Korn WM, Sze D, Kirn D, Reid TR. PMID: 17139321; PMCID: PMC7091580.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsCTClinical Trials
    27. Expression of the coxsackievirus- and adenovirus receptor in gastrointestinal cancer correlates with tumor differentiation. Cancer Gene Ther. 2006 Aug; 13(8):792-7. Korn WM, Macal M, Christian C, Lacher MD, McMillan A, Rauen KA, Warren RS, Ferrell L. PMID: 16628228.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    28. Transforming growth factor-beta receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of Coxsackie and Adenovirus Receptor in conjunction with reversal of epithelial-mesenchymal transition. Cancer Res. 2006 Feb 01; 66(3):1648-57. Lacher MD, Tiirikainen MI, Saunier EF, Christian C, Anders M, Oft M, Balmain A, Akhurst RJ, Korn WM. PMID: 16452224.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimalsCells
    29. Prevention and management of early esophageal cancer. Curr Treat Options Oncol. 2004 Oct; 5(5):405-16. Korn WM. PMID: 15341678.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    30. Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells. Cancer Res. 2003 May 01; 63(9):2088-95. Anders M, Christian C, McMahon M, McCormick F, Korn WM. PMID: 12727824.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCells
    31. Disruption of 3D tissue integrity facilitates adenovirus infection by deregulating the coxsackievirus and adenovirus receptor. Proc Natl Acad Sci U S A. 2003 Feb 18; 100(4):1943-8. Anders M, Hansen R, Ding RX, Rauen KA, Bissell MJ, Korn WM. PMID: 12576544; PMCID: PMC149938.
      View in: PubMed   Mentions: 37     Fields:    Translation:Cells
    32. ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br J Cancer. 2002 Jan 07; 86(1):5-11. Ries S, Korn WM. PMID: 11857003; PMCID: PMC2746528.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
    33. Moving toward an understanding of the metastatic process in hepatocellular carcinoma. World J Gastroenterol. 2001 Dec; 7(6):777-8. Korn WM. PMID: 11854899; PMCID: PMC4695592.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimals
    34. Chromosome arm 20q gains and other genomic alterations in colorectal cancer metastatic to liver, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization. Genes Chromosomes Cancer. 1999 Jun; 25(2):82-90. Korn WM, Yasutake T, Kuo WL, Warren RS, Collins C, Tomita M, Gray J, Waldman FM. PMID: 10337990.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    35. Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer. Anticancer Drugs. 1998 Mar; 9(3):203-7. Klaassen U, Wilke H, Weyhofen R, Harstrick A, Eberhardt W, Müller C, Korn M, Hanske M, Diergarten K, Seeber S. PMID: 9625430.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    36. Infusional 5-FU, folinic acid, paclitaxel, and cisplatin for metastatic breast cancer. Oncology (Williston Park). 1997 Apr; 11(4 Suppl 3):38-40. Klaassen U, Wilke H, Müller C, Borquez D, Korn M, Achterrath W, Harstrick A, Diergarten K, Seeber S. PMID: 9144690.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    37. Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5-fluorouracil. Anticancer Drugs. 1997 Mar; 8(3):293-5. Strumberg D, Harstrick A, Klaassen U, Müller C, Eberhardt W, Korn MW, Wilke H, Seeber S. PMID: 9095336.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    38. Use of fluorescence in situ hybridization and comparative genomic hybridization in the cytogenetic analysis of testicular germ cell tumors and uveal melanomas. Cancer Genet Cytogenet. 1997 Jan; 93(1):22-8. Becher R, Korn WM, Prescher G. PMID: 9062576.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    39. Detection of chromosomal DNA gains and losses in testicular germ cell tumors by comparative genomic hybridization. Genes Chromosomes Cancer. 1996 Oct; 17(2):78-87. Korn WM, Oide Weghuis DE, Suijkerbuijk RF, Schmidt U, Otto T, du Manoir S, Geurts van Kessel A, Harstrick A, Seeber S, Becher R. PMID: 8913724.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    40. Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur J Cancer. 1996 Mar; 32A(3):547-9. Klaassen U, Wilke H, Strumberg D, Eberhardt W, Korn M, Seeber S. PMID: 8814705.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    41. Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer. J Infus Chemother. 1996; 6(3):123-6. Wilke H, Korn M, Vanhöfer U, Fink U, Stahl M, Preusser P, Köhne C, Klassen U, Harstrick A, Schmoll HJ, Seeber S. PMID: 9229322.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    Michael's Networks
    Concepts (259)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (48)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.